WHO WE ARE.
SAPPIENS is a clinical-stage biotech pioneering first-in-class disease-modifying therapies for Parkinson’s disease and ALS, two devastating neurodegenerative diseases with major unmet needs. Its lead candidate, CXS003, simultaneously targets three key mechanisms: oxidative stress, neuroinflammation, and mitochondrial dysfunction. SAPPIENS combines experienced leadership, deep scientific expertise, strong Scientific Advisory Boards, and leading KOL networks.
THE NEED FOR NEUROPROTECTIVE TREATMENT FOR PARKINSON'S DISEASE
10 million people worldwide suffer from Parkinson's disease. It represents a considerable socio-economical cost, a rising incidence and a doubling of prevalence over 25 years and a real burden for caregivers and patients alike.
THE FUNCTION OF CURRENT TREATMENTS
Symptomatic treatments to counteract the neurons' deficient production of dopamine. Duration of action decreases as the disease progresses.
THE OBJECTIVE OF NEUROPROTECTIVE TREATMENT
Preserve or even restore the functionality of neurons that are still viable, to compensate for the reduced response to symptomatic treatments and slow down the progression to loss of autonomy.
As the WHO points out, "worldwide, disability and mortality attributable to Parkinson's disease are increasing rapidly".
CXS003 : A UNIQUE, MULTIFACETED NEUROPROTECTIVE DRUG CANDIDATE.
2 published patents in 2024 and 2025 covering several neurodegenerative diseases.
Robust data demonstrating CXS003 efficacy neuronal survival in Parkinson's disease and ALS.
CXS003 entering Phase 2 scheduled for 2028 and actually in preparation.
CXS003 restores
neuronal viability
The use of CXS003 restores neurite length and cell viability in an induced model of diseased neurons.
Healthy neurons
Diseased neurons
Diseased neurons + CXS003
*BDNF: brain-derived neurotrophic factor
CXS003 improves the survival of dopaminergic neurons in vivo and the behavioral phenotype.
Value Creation Roadmap
Next milestone in less than 18 months
A NETWORK OF EXCELLENCE
SUPPORTS OUR PROGRAM
Preclinical and clinical experts specializing in neurology, Parkinson’s disease, and ALS.
Hospitals integrating multidisciplinary research networks throughout France.
National and international foundations dedicated to fighting Parkinson’s disease and ALS, including associations.
OUR TEAM
Clinical and scientific expertise. Key partners recognized for their skills. A complementary team made up of passionate members.
GABRIELLE GACHE
General Manager
Co-founder and board member
C-level Executive from the Pharma-Biotech industry, Advisor and Board Member with 25+ years experience in Corporate and Business Dev., Licensing and Access. President of " Swiss Healthcare Licensing Group "from 2015 to 2022.
GUILLAUME BRACHET
Scientific management
Co-founder and board member
Pharmacist - researcher. Expert in pharmaceutical innovation and biomedicines. Diagnosed with Parkinson's disease in 2018.
NADINE MACKENZIE
Medical management
Co-founder and board member
Rheumatologist. Medical Director in the pharmaceutical industry for 20+ years. Former member of the Executive Committee of LEO Pharma France.
ANTHONY ALIOUI
Scientific Director
Co-founder and board member
PhD in genetics and molecular physiology. Expert in prevention and health promotion. Founder of the "MS PEDAGO" training organization.
Frédéric Charoy
Chief Financial Officer
–
15+ years of experience as a CFO in biotech/deep tech, formerly at Biogen. Seed and Series A fundraising from European and U.S. VCs. Expertise in financial strategy, investor relations, and due diligence.
A scientific board of experts supports us in the design of our early development plan.
DAVID
DEVOS
Neurologist, Research Fellow at Lille University Hospital, NS-PARK Executive Committee
SIMON
STOTT
Doctor in neurobiology and director of research at the " Parkinson's Cure "
MARIE
FUZZATI
Doctor in biology and scientific director of " France Parkinson "
ANNIE-SOPHIE
ROLLAND
Doctor in neuroscience and researcher at Lille University Hospital (LiLNCog center)
Other clinical experts, as well as the Michael J. Fox Foundation, are currently joining the project to validate the Phase 2 design and the biomarker strategy.
———————————————————-
An ALS-specific advisory scientific committee
is currently being established.
